The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in An Ethnically Diverse Patient Population with Advanced Pancreatic Cancer
- 15 Downloads
The neutrophil-to-lymphocyte ratio (NLR) is associated with decreased overall survival in patients with pancreatic adenocarcinoma (PAC) in studies including few minority patients. We investigated the association between NLR and survival in patients with advanced PAC in an ethnically diverse population.
We retrospectively evaluated 226 patients with advanced PAC treated at Montefiore Medical Center between 2006 and 2015. Adjusted Cox proportion hazard regression models were utilized to derive effect estimates for survival duration.
Patients with a NLR ≤ 5 (126 patients, median age 66 years) were more likely to be non-Hispanic Black (30.8% vs. 20%), while patients with a NLR > 5 (70 patients, median age 66 years) were more likely to be non-Hispanic White (21.4% vs. 12.2%) or Hispanic (44.3% vs. 34%). A NLR > 5 compared with a NLR ≤ 5 was significantly associated with a worse overall survival when adjusted for a priori and exploratory variables from the univariate analysis (median survival 7.4 vs. 12 months, HR 1.650, 95% CI 1.139, 2.390).
In an ethnically diverse population, elevated NLR is an independent marker of poor prognosis and a potentially valuable factor in driving therapeutic decisions and defining prognosis for patients in the locally advanced or metastatic for PAC setting, meriting investigation in prospective clinical trials.
KeywordsPancreatic cancer Inflammation Healthcare disparities Prognostic factors Chemotherapy
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 1.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016 (in eng). CA: Cancer J Clin. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332.
- 3.C. S. Yabar and J. M. Winter, “Pancreatic cancer: a review,” Gastroenterology Clinics of North America, vol. 45, no. 3, pp. 429-445, 9// 2016, https://doi.org/10.1016/j.gtc.2016.04.003.
- 4.Burris HA 3rd, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial in eng. J Clin Oncol : Off J Am Soc Clin Oncol. 1997;15(6):2403–13. https://doi.org/10.1200/jco.1918.104.22.1683.CrossRefGoogle Scholar
- 5.D. D. Von Hoff et al., Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine(in eng) N Engl J Med, vol. 369, no. 18, pp. 1691-703, Oct 31 2013, 10.1056/NEJMoa1304369.Google Scholar
- 6.T. Conroy et al., “FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer,” (in eng), The New England journal of medicine, vol. 364, no. 19, pp. 1817-25, May 12 2011, 10.1056/NEJMoa1011923.Google Scholar
- 8.T. M. Bauer et al., Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials in eng, Cancer, vol. 119, no. 2, pp. 285-92, Jan 15 2013, 10.1002/cncr.27734.Google Scholar
- 9.M. Haas et al., “Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy,” (in eng), J Cancer Res Clin Oncol, vol. 139, no. 4, pp. 681-689, 2013, https://doi.org/10.1007/s00432-012-1371-3.
- 11.Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer (in eng). Cell. 140(6):883–99, Mar 19 2010. https://doi.org/10.1016/j.cell.2010.01.025.
- 16.Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, et al. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients (in eng). Cancer Med. 2014;3(2):406–15. https://doi.org/10.1002/cam4.204.
- 17.Kou T, Kanai M, Yamamoto M, Xue P, Mori Y, Kudo Y, et al. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Int J Clin Oncol. 2016;21(1):118–25. https://doi.org/10.1007/s10147-015-0864-x.
- 18.Goldstein D, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial(in eng). J Natl Cancer Inst. 2015;107(2). https://doi.org/10.1093/jnci/dju413.
- 19.Wang-Gillam A, Hubner RA, Siveke JT, von Hoff D, Belanger B, de Jong FA, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors (in eng). Eur J Cancer. 2019;108:78–87. https://doi.org/10.1016/j.ejca.2018.12.007.
- 23.Silverman DT, et al. Why do Black Americans have a higher risk of pancreatic cancer than White Americans? Epidemiology Cambridge, Mass. 2003;14(1):45–54. https://doi.org/10.1097/01.ede.0000034393.39604.ff.CrossRefPubMedGoogle Scholar
- 24.Bellin E, Fletcher DD, Geberer N, Islam S, Srivastava N. Democratizing information creation from health care data for quality improvement, research, and education-the Montefiore Medical Center Experience. Acad Med : J Assoc Am Med Coll. 2010;85(8):1362–8. https://doi.org/10.1097/ACM.0b013e3181df0f3b.CrossRefGoogle Scholar
- 26.Park HS, Lee HS, Park JS, Park JS, Lee DK, Lee SJ, et al. Prognostic scoring index for patients with metastatic pancreatic adenocarcinoma. Cancer Res Treat. 2016;48(4):1253–63. https://doi.org/10.4143/crt.2015.400.
- 28.D. Reich et al., Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene(in eng) PLoS Genet, vol. 5, no. 1, p. e1000360, 2009, 10.1371/journal.pgen.1000360.Google Scholar
- 32.Bausch D, Pausch T, Krauss T, Hopt UT, Fernandez-del-Castillo C, Warshaw AL, et al. Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma (in eng). Angiogenesis. 2011;14(3):235–43. https://doi.org/10.1007/s10456-011-9207-3.
- 33.Grosse-Steffen T, Giese T, Giese N, Longerich T, Schirmacher P, Hänsch GM, et al. Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma and pancreatic tumor cell lines: the role of neutrophils and neutrophil-derived elastase in eng. Clin Dev Immunol. 2012;2012:720768. https://doi.org/10.1155/2012/720768.